State Street Corp grew its holdings in Zogenix, Inc. (NASDAQ:ZGNX) by 9.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 446,593 shares of the company’s stock after purchasing an additional 38,588 shares during the quarter. State Street Corp owned about 1.80% of Zogenix worth $6,474,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of ZGNX. SG Americas Securities LLC acquired a new stake in shares of Zogenix in the second quarter valued at about $100,000. Stifel Financial Corp acquired a new stake in shares of Zogenix in the second quarter valued at about $175,000. Voya Investment Management LLC grew its position in shares of Zogenix by 13.5% in the second quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock valued at $205,000 after purchasing an additional 1,686 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its position in shares of Zogenix by 17.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 19,734 shares of the company’s stock valued at $214,000 after purchasing an additional 2,864 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Zogenix in the second quarter valued at about $231,000. 73.47% of the stock is currently owned by institutional investors.
In other news, major shareholder Life Sciences Maste Perceptive bought 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were acquired at an average cost of $37.50 per share, with a total value of $11,250,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.00% of the stock is owned by company insiders.
Shares of Zogenix, Inc. (NASDAQ ZGNX) opened at $38.90 on Friday. Zogenix, Inc. has a 1 year low of $7.70 and a 1 year high of $42.60. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.71.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).
What are top analysts saying about Zogenix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zogenix Inc. and related companies.